These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 18157010)

  • 1. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
    Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
    J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
    Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
    J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.
    Sonoda T; Sugimura K; Ikemoto S; Kawashima H; Nakatani T
    Oncol Rep; 2007 Jun; 17(6):1469-74. PubMed ID: 17487406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
    Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
    J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity.
    O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
    J Urol; 2004 Mar; 171(3):1330-5. PubMed ID: 14767343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
    De Boer EC; Rooijakkers SJ; Schamhart DH; Kurth KH
    J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.
    Suttmann H; Riemensberger J; Bentien G; Schmaltz D; Stöckle M; Jocham D; Böhle A; Brandau S
    Cancer Res; 2006 Aug; 66(16):8250-7. PubMed ID: 16912205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
    Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of bacillus Calmette-Guérin-induced nitric oxide in bladder tumor cells may improve BCG treatment.
    Alvarez V; Lodillinsky C; Umerez S; Sandes E; Eiján AM
    Int J Mol Med; 2005 Oct; 16(4):565-71. PubMed ID: 16142388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
    Chang SG; Lee SJ; Huh JS; Lee JH
    Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing syngeneic orthotopic murine bladder cancer (MB49).
    Günther JH; Jurczok A; Wulf T; Brandau S; Deinert I; Jocham D; Böhle A
    Cancer Res; 1999 Jun; 59(12):2834-7. PubMed ID: 10383142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation.
    Udagawa M; Kudo-Saito C; Hasegawa G; Yano K; Yamamoto A; Yaguchi M; Toda M; Azuma I; Iwai T; Kawakami Y
    Clin Cancer Res; 2006 Dec; 12(24):7465-75. PubMed ID: 17189420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer.
    Sänger C; Busche A; Bentien G; Spallek R; Jonas F; Böhle A; Singh M; Brandau S
    BMC Cancer; 2004 Nov; 4():86. PubMed ID: 15566565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model.
    Loskog AS; Fransson ME; Totterman TT
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8816-21. PubMed ID: 16361570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model.
    Horinaga M; Harsch KM; Fukuyama R; Heston W; Larchian W
    Urology; 2005 Aug; 66(2):461-6. PubMed ID: 16040105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.
    Chen F; Zhang G; Cao Y; Hessner MJ; See WA
    J Urol; 2009 Dec; 182(6):2932-7. PubMed ID: 19853870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fibronectin attachment protein of bacillus Calmette-Guerin (BCG) mediates antitumor activity.
    Sinn HW; Elzey BD; Jensen RJ; Zhao X; Zhao W; Ratliff TL
    Cancer Immunol Immunother; 2008 Apr; 57(4):573-9. PubMed ID: 17786441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model.
    Hegele A; Dalpke A; Barth P; Varga Z; Heeg K; Hofmann R; Olbert P
    Anticancer Res; 2004; 24(4):2225-30. PubMed ID: 15330165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.